Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 5/20 | 0.65 |
| ▸ | LPAR5 | Q9H1C0 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RXRA | P19793 | 1/20 | 0.59 |
| ▸ | RXRB | P28702 | 1/20 | 0.59 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784341 | 1.00 | LPAR1 (0.65) | LPAR1LPAR5HPGDRXRARXRB | |
| SCHEMBL27874065 | 0.88 | SRD5A2 (0.56) | LPAR1LPAR5SRD5A2MAPK14XIAP | |
| SCHEMBL7706043 | 0.87 | SRD5A2 (0.68) | LPAR1LPAR5SRD5A2NR4A2TTR | |
| Hydrochloric Acid SCHEMBL8433842 | 0.85 | SRD5A2 (0.66) | LPAR1LPAR5SRD5A2NR4A2TTR | |
| Hydrochloric Acid SCHEMBL8433836 | 0.85 | SRD5A2 (0.66) | LPAR1LPAR5SRD5A2NR4A2TTR | |
| SCHEMBL6341056 | 0.84 | MRGPRX4 (0.55) | LPAR1LPAR5HPGDRXRARXRB | |
| SCHEMBL11511159 | 0.84 | MAPT (0.60) | LPAR1LPAR5HPGDMAPK14XIAP | |
| SCHEMBL27480252 | 0.84 | PARP10 (0.66) | LPAR1LPAR5MAPK14XIAPEZH2 | |
| SCHEMBL7176453 | 0.82 | DPP4 (0.53) | LPAR1LPAR5HPGDMAPK14XIAP | |
| SCHEMBL27704809 | 0.82 | LPAR1 (0.49) | LPAR1LPAR5HPGDRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
| EP-3523292-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | Dong-A Socio Holdings Co., Ltd. (KR) | 2019-08-14 | — | — | EP | disclosed |
| US-20190010129-A1 | Amide derivatives as lysophosphatidic acid receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2019-01-10 | — | — | US | disclosed |
| US-20160207880-A1 | AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3036215-A1 | AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-06-29 | — | — | EP | disclosed |
| CN-105473548-A | Amide derivatives as lysophosphatidic acid receptor antagonists | TAKEDA PHARMACEUTICALS CO | 2016-04-06 | — | — | CN | disclosed |
| WO-2015025164-A1 | AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057298-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2015-02-26 | — | — | US | disclosed |
| EP-1873153-B1 | 3-AZETIDINECARBOXYLIC ACID DERIVATIVES FOR USE AS IMMUNOSUPPRESSANTS | DAIICHI SANKYO CO LTD (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-7687491-B2 | Heterocyclic compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-30 | — | — | US | disclosed |
| CN-101203512-A | Heterocyclic compounds | DAIICHI SANKYO CO LTD (JP) | 2008-06-18 | — | — | CN | disclosed |
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1873153-A1 | HETEROCYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | LPAR1 318/4885LPAR5 758/4885HPGD 4439/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | LPAR1 513/4885LPAR5 1195/4885HPGD 4353/4885 |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | LPAR1 318/4885LPAR5 758/4885HPGD 4439/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | LPAR1 513/4885LPAR5 1195/4885HPGD 4353/4885 |
| US-20190010129-A1 | Amide derivatives as lysophosphatidic acid receptor antagonists | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885LPAR5 5/4885HPGD 3054/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | LPAR1 240/4885LPAR5 283/4885HPGD 4094/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | LPAR1 240/4885LPAR5 283/4885HPGD 4094/4885 |
| US-20080113961-A1 | Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds | TPMT, AZI2, IDO1 | LPAR1 2850/4885LPAR5 2886/4885HPGD 1473/4885 |
| US-20160207880-A1 | AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885LPAR5 5/4885HPGD 3203/4885 |
| US-20150057298-A1 | NOVEL COMPOUNDS | F12, C1R, CHRM1 | LPAR1 421/4885LPAR5 1052/4885HPGD 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.